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EDITORIAL
Measuring Successful Treatment of Irritable Bowel
Syndrome: Is “Satisfactory Relief ” Enough?
Philip Schoenfeld, M.D., MSEd., M.Sc. (Epi)1 and Nicholas J. Talley, M.D., Ph.D.2
1Division of Gastroenterology, University of Michigan School of Medicine, Ann Arbor, Michigan, and 2Division
of Gastroenterology, Mayo Clinic College of Medicine
The treatment options for the irritable bowel syndrome (IBS) are expanding as new therapies, including probiotics
and serotonin receptor agents, become available. Before any new agents gain widespread use, they must be
studied in appropriately designed clinical trials. Symptom improvement remains the key clinically but the best
technique to measure symptom improvement is unclear. Many IBS therapy studies have used a binary endpoint
such as “Have you had satisfactory relief of your IBS symptoms in the past week? Yes/No?” The study by
Whitehead and colleagues in this issue suggests that “satisfactory relief” is affected by baseline symptom severity
and may not always truly reflect the symptom burden. Future research needs to determine whether “satisfactory
relief” is truly adequate, or whether alternatives such as the proportion of patients achieving a ≥50% reduction in
symptom severity would represent a superior approach to capture clinically important improvement.
(Am J Gastroenterol 2006;101:1066–1068)
Based on recent evidence, it appears likely that irritable
bowel syndrome (IBS) is an organic gut-brain disorder; key
pathophysiologic defects in subsets of IBS patients include
increased sensitivity to colonic distention and altered central
pain processing, abnormal colonic serotonin receptor signal-
ing, low grade colonic inflammation, and possibly an abnor-
mal enteric bacterial-immune interface (1–4). However, there
is as yet no accepted biological disease marker. Furthermore,
there is no obvious marker to utilize when assessing the sever-
ity of IBS symptoms or IBS symptom improvement, unlike
gastroesophageal reflux disease (GERD) where the sever-
ity of esophagitis can be assessed endoscopically and heal-
ing documented. The functional bowel disease severity scale
purports to assess IBS severity but was validated only against
physician judgment and is confounded by office visits over
the previous 6 months, which limits its value (5). Therefore,
IBS researchers and clinicians must still rely upon symptom
improvement to measure successful treatment of IBS.
Given this dilemma, the Rome Committee on treatment tri-
als (6) recommended that the primary endpoint in IBS therapy
trials was best assessed by a global subjective improvement
in IBS symptoms. This endpoint had the advantage of poten-
tially encompassing improvement in the multiple symptoms
of IBS, including abdominal discomfort, bloating, and stool
consistency. The U.S. Food and Drug Administration has ac-
cepted subjective global improvement in IBS symptoms as a
primary endpoint (7), especially when assessed using a binary
(yes/no) measure such as “In the last seven days, have you had
adequate (or satisfactory) relief of your IBS symptoms?” We
must ask if this simple binary endpoint, “satisfactory relief
of IBS symptoms,” is optimal to determine if an IBS patient
has been successfully treated.
In this issue of the journal, Whitehead and colleagues (8)
report their analysis of patients receiving standard medical
care for IBS at a large health maintenance organization (9).
In this secondary analysis, the authors looked at the results
of a “satisfactory relief” endpoint measured with a binary
question. They compared these results to a seven-point Lik-
ert scale rating subjective improvement in gastrointestinal
symptoms and to the magnitude of symptom reduction using
a valid IBS symptom severity questionnaire. The investiga-
tors sought to determine if initial IBS symptom severity in-
fluences the likelihood of achieving “satisfactory relief” and
if it influenced the magnitude of IBS symptom reduction. The
investigators found that patients with mild IBS symptoms at
baseline were much more likely to achieve “satisfactory re-
lief” of IBS symptoms after treatment compared to patients
with severe IBS symptoms at baseline (72% vs 44%, respec-
tively; p < 0.001). However, when satisfactory response to
therapy was determined by a ≥50% reduction in IBS symp-
toms from baseline, patients with mild IBS symptoms and
patients with severe IBS symptoms [defined by an IBS symp-
tom severity scale (10)] had a similar likelihood of achieving
this endpoint (26% vs 23%, respectively; p = ns). Notably,
by adjusting the IBS symptom score for baseline values, the
deck was stacked against satisfactory relief here, but this
is the point: satisfactory relief was confounded by baseline
symptom severity in this study. Therefore, if achievement of
“satisfactory relief” is the primary endpoint of an IBS therapy
trial, then it may be relatively easy to achieve this endpoint
if most of the patients have “mild” IBS symptoms. However,
a 50% reduction in symptoms in a patient with severe IBS
symptoms is potentially an important finding and probably
represents a clinically meaningful change even if the patient
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with severe IBS symptoms does not achieve “satisfactory
relief.” Given these results, Whitehead and colleagues spec-
ulate that binary endpoints measuring “satisfactory relief”
may not be optimal to detect a clinically meaningful change
and hence may miss real benefits in clinical trials. However,
the limitations of this study (8) must be remembered. This
was an observational study rather than a randomized con-
trolled trial and may be subject to numerous biases that could
have exaggerated the results.
If “satisfactory relief” endpoints are confounded by ini-
tial IBS symptom severity, then what should be the primary
endpoint? A 50% reduction in global symptom severity?
Complete or near complete resolution of symptoms? Sig-
nificant improvement in the score of a validated quality-of-
life questionnaire? The recommendations of the Rome Com-
mittee on treatment trials (6) provide some guidance about
this topic.
1. A subjective global assessment of IBS symptom improve-
ment should be used as the primary endpoint. This sub-
jective global endpoint should allow the patient to assess
improvement in multiple IBS symptoms (e.g., abdominal
discomfort, bloating, stool consistency, stool frequency,
etc.) because improvement in a single symptom (e.g., stool
frequency) may not be adequate to demonstrate true im-
provement in IBS.
2. IBS therapy trials should measure individual IBS symp-
toms (e.g., abdominal discomfort, bloating, etc.) as sec-
ondary endpoints. If patients demonstrate significant im-
provement in the primary endpoint of subjective global
improvement in IBS symptoms, then this finding is rein-
forced if significant improvement is also demonstrated in
individual IBS symptoms.
3. IBS therapy trials should also measure symptom improve-
ment with a validated quality-of-life questionnaire. If a
treatment is associated with a significant improvement in
quality of life, then this also reinforces the benefits of an
IBS therapy.
Various quality-of-life questionnaires have been applied in
IBS therapy trials. Some questionnaires are generic (e.g., SF-
36) and can be utilized to measure changes in quality of life for
any disorder, such as depression or diabetes mellitus. How-
ever, these questionnaires evaluate such broad categories that
they may not be able to measure clinically important changes
in quality of life for a specific disorder like IBS. IBS-specific
questionnaires, such as the IBS-QOL (11) and the IBS sever-
ity scoring system (IBS-SSS) (10), are available for use in
IBS patients, but we do not know what constitutes a “clin-
ically important improvement” in scores on these validated
questionnaires. Complete symptom relief has proven a very
useful endpoint in GERD trials assessing proton pump in-
hibitor therapy. Certainly, complete relief of symptoms is con-
vincing evidence of efficacy if placebo is beaten; further, we
strongly recommend results on complete relief of active ther-
apy and placebo should always be reported in clinical trials of
IBS treatments as a secondary endpoint. However, it seems
unlikely that current agents would frequently completely re-
solve all IBS symptoms even if the treatment produced “sat-
isfactory relief.” Therefore, complete relief of symptoms
is not optimal as a primary endpoint in IBS therapy trials
now.
The value of “satisfactory relief” in IBS therapy trials re-
lates to its ability to integrate various symptoms and the im-
pact of therapy on various symptoms; it is also easy to un-
derstand and it fits with the practice of medicine in the office
setting. When we see patients for return visits in our office,
our first question is frequently a global one such as “How are
you doing?” If a patient with IBS replies that they are doing
much better in terms of their IBS symptoms, then this ques-
tion seems to usefully provide a rapid assessment of relevant
symptom relief. A positive answer suggests that the patient
has undergone a clinically important improvement in their
symptoms. Therefore, we believe that a binary assessment of
“satisfactory relief” endpoints is useful in IBS therapy trials.
Based on the data provided by Whitehead and colleagues (5),
we suggest it is important for investigators to also measure
IBS symptom severity utilizing a validated scale. Investiga-
tors should consider reporting the proportion of IBS patients
with mild, moderate, or severe symptoms, since this may in-
fluence the proportion of patients who undergo “satisfactory
relief” of their IBS symptoms. Furthermore, we agree with
Whitehead and colleagues (5) that measurement of ≥50%
reduction in IBS symptoms is most likely associated with a
clinically important improvement in IBS symptoms and that
this is worth assessing as a secondary endpoint; more data are
needed before its use as a primary endpoint could be consid-
ered. Consistent with the Rome Committee recommendations
(3), we also agree that individual IBS symptoms of abdom-
inal discomfort, bloating, and stool consistency, should be
measured as secondary endpoints, and this can usually be
performed satisfactorily with Likert scales or visual analog
scales. However, we do not think that these should be primary
endpoints because minimally clinically important improve-
ments in individual symptoms measured by visual analog
scales or Likert scales have not been defined in IBS. Finally,
the use of validated quality-of-life questionnaires should be
considered a tertiary endpoint at this time since the minimal
clinically important improvement in IBS-specific quality-of-
life scores also remain unclear.
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